Get the latest news, insights, and market updates on CDT (CDT Equity Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
CDT Equity Notes Sarborg Filing of U.S. Provisional Patent Application for AI Signature Agent
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 05, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today notes the announcement issued by Sarborg Limited (“Sarborg”) regarding the filing of a U.S. provisional patent application relating to its proprietary AI Signature Agent. CDT holds a 20% equity stake in Sarborg and views this filing as an important step in strengthening and formalising Sarborg’s intellectual property position. Sarborg announced that a provis Mar 5, 2026 - $CDT
CDT Positions for Transformational Growth
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 04, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) advances multiple initiatives designed to enhance shareholder value and expand its strategic footprint. The Company continues to actively develop and expand its pharmaceutical asset portfolio, including solid-form and cocrystal development programs, alongside its licensed clinical assets AZD1656, AZD5658 and AZD5904 under its agreement with AstraZeneca. CDT remain Mar 4, 2026 - $CDT
CDT Equity Notes Sarborg Expansion into Bacteria and Agrochemicals
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 24, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement issued this morning by Sarborg Limited regarding the expansion of its proprietary AI Signature Agent platform beyond pharmaceuticals into bacteria and agrochemicals. CDT holds a significant 20% equity stake in Sarborg and views this expansion as a meaningful strategic development in the continued evolution of Sarborg’s cross-industry s Feb 24, 2026 - $CDT
CDT Acquires Strategic Stake in Sarborg to Transform its AI-Driven Asset Strategy
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 20, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that it has entered into a strategic transaction to acquire a 20% equity stake in Sarborg Limited (“Sarborg”), an agentic AI signature intelligence business operating across multiple industrial sectors. The investment formalizes and deepens the existing collaboration between CDT and Sarborg, which has already supported the evaluation of CDT’s clini Feb 20, 2026 - $CDT
CDT Equity Inc. Announces Reverse Stock Split
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 09, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), announces that its board of directors has approved a 1-for-8 reverse stock split of the Company’s common stock. The Company’s stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios, at the Company’s Special Meeting of Stockholders held on May 5, 2025. The directors expect Oct 9, 2025 - $CDT
CDT Equity Identifies New Biological Target Validating AI-Driven Repurposing Strategy
Using AI, CDT Equity Inc. identifies a novel therapeutic indication for its lead programmes, supported by successful pre-clinical trial dataNAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 26, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announces that it has successfully identified a new biological target and novel therapeutic indication for its lead programme, AZD1656 (and its derivatives), following positive data from pre-clinical studies. This affirms Aug 26, 2025 - $CDT
Conduit to Change Name to CDT Equity Inc.
Name change to CDT Equity Inc. reflects evolution of strategy and focus on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation, strategic partnerships and out-licensing NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit" or the “Company”) today announce that it intends to change its name to CDT Equity Inc. (“CDT”) reflecting the evolution of its strategy as a data-dri Aug 5, 2025 - $CDT
Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health
Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to capture commercial potential in the $15 billion animal health marketEvaluation of AZD5658 expands Conduit’s glucokinase activator platform into novel veterinary applications, complementing AZD1656 developmentCost-efficient approach enhances Conduit’s pipeline while preserving full ownership of intellectual property and data, maximizing shareholder valu Jun 4, 2025 - $CDT
Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 22, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development, announces that, following confirmation of compliance with the Bid Price and Equity Requirements as detailed in the announcement dated May 21, 2025, the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) that th May 22, 2025 - $CDT
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple